Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-rhG-CSF for Neutropenia in Cervical Cancer
NCT03206684Phase 4Unknown
- Sponsor
- Air Force Medical University
- Start
- Aug 2017
- Primary completion
- Jul 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pegfilgrastim in neutropenia (2 arms), sponsored by Air Force Medical University. Primary endpoint: Incidence of III/IV neutropenia at 3 months. Status: unknown.
02
Drugs
pegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT03206684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03206684.